Stop data brokers from exposing your personal information. Go to my sponsor: to get a 14-day free trial and see how much of yours is being sold. Then learn about the NEW BEST Priority Pass Credit Card ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or ...

Background Racial and ethnic disparities in infectious disease burden have been reported in the USA and globally, most recently during the COVID-19 pandemic. It remains unclear whether such ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

Illustrative image **media[706411]** Boehringer image library This press release is not intended for UK media.  HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% ...

In an era where legacy structures can no longer keep pace with rising costs, workforce disruption, and rapidly evolving technologies, healthcare leaders are reimagining the very core of how their ...

Khyber Pakhtunkhwa Chief Minister Ali Amin Khan Gandapur on Friday chaired the Deputy Commissioners (DCs) Conference on Thursday and ...

The Quantum Frederick data center campus is one of six projects selected as part of a pilot program to expedite Maryland’s permitting review process, the office of Gov. Wes Moore announced on Tuesday.

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

The Trump administration’s move to reduce requirements has puzzled some legal experts while drawing applause from oil states.

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...